PREDICTION OF REMISSION IN CHILDREN AND ADOLESCENTS WITH GRAVES' DISEASE: UTILIT

患有格雷夫斯病的儿童和青少年的缓解预测：UTILIT

• 批准号: 7380771
• 负责人: Rosalind Brown
• 金额: $ 1.33万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380771
• 关键词: PREDICTION; REMISSION; CHILDREN; ADOLESCENTS; GRAVES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HYPOTHESES AND SPECIFIC OBJECTIVES: The objectives of this proposal will be to: 1) Prospectively follow a group of children and adolescents with newly diagnosed Graves' disease 2) Measure thyroid function tests (T4, Free T4, Total T3, and TSH), TSH receptor antibodies (by both ELISA and bioassay), and TSH receptor antibody oligoclonality (as assessed by lambda/kappa ratio) at diagnosis, 6 months, and 12 months 3) Determine whether initial severity of hyperthyroidism (as determined by both clinical and hormonal parameters) is related to initial TSH receptor Ab potency and/or oligloclonality or both 4) Determine whether TSH receptor Ab titer at 6 months and at 12 months is related to: a) initial severity of hyperthyroidism (as determined by both clinical and hormonal parameters) b) initial TSH receptor Ab potency (by both ELISA and bioassay) c) initial TSH receptor Ab oligoclonality, as well as TSH receptor Ab oligoclonality at 6 months and 12 months 5) Characterize the course of TSH receptor Ab heterogeneity at diagnosis, 6 months and 12 months in individual patients; We hypothesize that: 1) Amongst children with Graves' disease, 75% will have TSH receptor Abs that are polyclonal as assessed by lambda/kappa ratio and 25% will have oligoclonal Abs 2) Oligoclonal Abs are more potent and affected patients have more severe disease and are less likely to remit 3) Those patients who have the most severe disease at diagnosis will have the highest TSH receptor Ab titers and will be less likely to remit on medical therapy 4) 25% of patients will have a change in clonality with disease progression.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。假设和特定目标：该提案的目标将是：1）前瞻性跟随一群具有新诊断的坟墓的儿童和青少年的疾病2）测量甲状腺功能测试（T4，FREE T4，TOR TOR T3和TSH），TSH受体抗体（通过Elisa和BioAssay和Tsh Assaby/Tshe Assabody Anty ofbody Oligagy Oligaine（由TSH受体抗体）比率）在诊断时，6个月和12个月3）确定与初始TSH受体AB效率和/或寡聚性的初始严重程度（由临床和激素参数确定）是否与初始TSH受体AB效率和/或寡量相关或两者相关4）确定6个月的TSH受体titer titer在6个月和12个月是否与以下方面的临床（a）确定的临床（A）确定的临床（A）最初的TSH受体AB效力（通过ELISA和生物测定）c）初始TSH受体AB寡聚性，以及在6个月零12个月的TSH受体AB寡聚性5）在诊断患者的6个月和12个月时TSH受体AB异质性的过程表征了TSH受体AB异质性的进程；我们假设：1）在患有坟墓疾病的儿童中，有75％的TSH受体ABS是多克隆的TSH受体ABS，由Lambda/kappa比例评估，而25％的abs和25％的abs abs 2）寡聚体ABS 2）寡群ABS的寡聚腹肌更有效，并且受到较少的患者的可能性更少，而受体的可能性更少。医疗治疗的份额4）25％的患者将随着疾病进展的克隆性而改变。